• Users Online: 1633
  • Print this page
  • Email this page
Year : 2008  |  Volume : 52  |  Issue : 5  |  Page : 556

Pre-Emptive Analgesia for Elective Maxillofacial Surgery Using 0.25% Bupivacaine

1 Associate Professor (Anesthesiology), Ragas Dental College and Hospital, Chennai, India
2 PG. Student, Dept. of Oral and Maxillofacial Surgery, Ragas Dental College and Hospital, Chennai, India
3 HOD, Dept. of Oral and Maxillofacial Surgery Ragas Dental College and Hospital, Chennai, India

Correspondence Address:
Radhika Krishnan
G 203, Atrium, 22, Kalakshetra road, Thiruvanmiyur, Chennai 600041
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

The efficacy of 0.25% bupivacaine as a pre-emptive analgesic agent was evaluated in a prospective case control study - a group of patients undergoing elective orthognathic surgery against a matched control group. Bupivacaine was administered as a series of nerve blocks prior to the incision for the surgery. Outcome variables measured were postoperative pain by Visual Analogue Scale (VAS) score, need and amount of rescue analgesics and the incidence of known complications associated with these agents. The VAS score was significantly lower in the group receiving pre-emptive analgesia for upto 40 hours postoperatively, (P<0.05). The amount of rescue analgesics administered and the incidence of complications attributed were less in study group than that of the control group, (P>0.05). Bupivacaine can be used for pre-emptive analgesia in oral and maxillofacial surgery.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded595    
    Comments [Add]    

Recommend this journal